ReviewThe pharmacogenomics journal2007
Molecular therapy in the microRNA era.
Review in The pharmacogenomics journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- The role of NLRP3 inflammasome in hepatocellular carcinoma.Frontiers in pharmacology · 2023Review
- Non-coding RNA in rhabdomyosarcoma progression and metastasis.Frontiers in oncology · 2022Review
- MiR-223-3p inhibits rTp17-induced inflammasome activation and pyroptosis by targeting NLRP3.Journal of cellular and molecular medicine · 2020Article
- MiR-216a-5p-containing exosomes suppress rTp17-induced inflammatory response by targeting TLR4.Bioscience reports · 2019Article
- Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.Cancers · 2019Review
- miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1.Oncology letters · 2018Article
- MicroRNA-129-3p functions as a tumor suppressor in serous ovarian cancer by targeting BZW1.International journal of clinical and experimental pathology · 2018Article
- The Network of Non-coding RNAs in Cancer Drug Resistance.Frontiers in oncology · 2018Review
- Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.Gene therapy · 2015Article
- Recombinant adeno-associated virus-mediated inhibition of microRNA-21 protects mice against the lethal schistosome infection by repressing both IL-13 and transforming growth factor beta 1 pathways.Hepatology (Baltimore, Md.) · 2015Article
- MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1.World journal of gastroenterology · 2015Article
- Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.Molecular carcinogenesis · 2014Article
- TGF-β1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma.Oncogene · 2014Article
- Rational design of microRNA-siRNA chimeras for multifunctional target suppression.RNA (New York, N.Y.) · 2013Article
- MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation.PloS one · 2013Article
- Modeling of non-steroidal anti-inflammatory drug effect within signaling pathways and miRNA-regulation pathways.PloS one · 2013Article
- Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing.Molecular pharmaceutics · 2012Article
- Article
- Cancer epigenetics: above and beyond.Toxicology mechanisms and methods · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) consist of a growing class of non-coding RNAs (ncRNAs) that negatively regulate the expression of genes involved in development, differentiation, proliferation, apoptosis and other important cellular processes. miRNAs are usually 18-25 nt long and are each able to regulate several mRNAs by mechanisms such as incomplete base pairing and Post-Transcriptional Gene Silencing (PTGS). A growing number of reports have shown that aberrant miRNA expression is a common feature of human diseases including cancer, which has sparked interest in targeting these regulators of gene expression as a means of ameliorating these diseases. Here, we review important aspects of miRNA function in normal and pathological states and discuss new modalities of epigenetic intervention strategies that could be used to amend defects in miRNA/mRNA interactions.
Indexed as
Identifiers
17189960What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.